In order to develop new strategies for the treatment of relapsed or refractory acute myeloid leukemia, the German AML Cooperative Group performed a prospective multicenter phase II study to evaluate the antileukemic efficacy of aclarubicin 60 mg/m 2 /day and etoposide 100 mg/m 2 /day each given for 5 days. Of 37 heavily pretreated evaluable patients (median age 42 years, range 18-81) 15 (40%) achieved a remission after one or two courses of treatment consisting of nine complete (24%) and six partial remissions (16%). Fourteen (38%) cases were non-responders and eight (22%) patients suffered from early deaths. Disease-free survival for patients in remission and overall survival were 3.2 months each. The median duration of critical neutropenia Ͻ500/l was 27 days. The most frequent non-hematologic side-effects were stomatitis (WHO III/IV, 48%), infections (40%), nausea/vomiting (26%) and diarrhea (24%). Cardiac toxicity was mild. This study suggests a substantial antileukemic efficacy and an acceptable toxicity of aclarubicin in combination with etoposide in heavily pretreated patients with advanced acute myeloid leukemia, and warrants further evaluations in a more favorable stage of the disease.
Introduction
Although long-term remissions can be achieved in approximately one-third of patients with acute myeloid leukemia (AML), mostly by combinations of an anthracycline with standard-or high-dose cytosine arabinoside, 1,2 the majority of patients experience a relapse and ultimately die from resistant and progressive disease. [3] [4] [5] New treatment modalities are therefore needed to improve the long-term perspectives for adult patients with AML. Non-cross-resistant drug combinations may complement established regimens and may support this goal.
Exhibiting relatively low levels of cross-resistance with doxorubicin and daunorubicin, 6, 7 aclarubicin is a promising alternative to older anthracyclines and may be less hampered in impairing cytotoxicity by the expression of p-glycoprotein. 8, 9 The topoisomerase-II inhibitor etoposide reveals substantial antileukemic efficacy as single agent with only limited toxicity 10, 11 and is rarely used in first-line treatment. Stimulated by promising reports by Rowe et al 12 and preliminary first own results, 13 the German AML Cooperative Group initiated a prospective multicenter phase II study to evaluate the antileukemic potential of combination therapy with aclarubicin and etoposide in patients with advanced heavily pretreated AML. 
Patients and methods

Patients
Consecutive patients at ages 18 or older with AML refractory to a first salvage attempt or with second or subsequent relapses who were admitted at the participating centers between August 1988 and November 1990 were eligible for the study. The diagnosis of AML was based on the revised French-American-British (FAB) Group criteria. 14 All patients were recruited from the first and second line trials of the German AML Cooperative Group and the South German Hemoblastosis Group and had thus received a standardized prior treatment. First-line therapy consisted of conventional induction therapy with either TAD-9 (thioguanine, cytosine arabinoside, daunorubicin) or DAV (daunorubicin, cytosine arabinoside, etoposide), or double induction with either TAD-9/TAD-9, DAV/DAV or TAD-9/HAM (high-dose cytosine arabinoside and mitoxantrone). A second course of induction therapy was applied to patients older than 60 years only upon inadequate response to the first TAD-9 or DAV cycle. Patients of all ages who achieved a complete remission subsequently received TAD-9 or DAV for consolidation and monthly maintenance therapy for 3 years. [15] [16] [17] Second-line treatment consisted of TAD-9 or the sequential high-dose cytosine arabinoside and mitoxantrone regimen (S-HAM). 4 Patients with antecedent hematologic disorders, secondary leukemias, and a preceding autologous or allogeneic bone marrow transplantation were excluded from the study. Further exclusion criteria comprised coronary heart disease, heart failure, cardiomyopathy, severe arterial hypertension, abnormal liver function tests (aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase (AP) more than three times the upper normal limits, total bilirubin Ͼ2.0 mg/dl), impaired renal function (serum creatinine Ͼ2.0 mg/dl), severe infections, or pregnancy.
Antileukemic therapy
Patients meeting the entry criteria were enrolled in the study and were treated with aclarubicin 60 mg/m 2 /day and etoposide 100 mg/m 2 /day as a 30-min infusion on days 1-5, respectively. Patients not achieving a complete or partial remission by the first course could receive a second course of the identical regimen.
Study parameters
Response to therapy was assessed according to CALGB criteria. 18 Complete remission (CR) was defined as a normal cellular bone marrow with normal erythroid and myeloid elements and less than 5% myeloblasts, and with peripheral blood counts of more than 100 000/l platelets and more than 1500/l granulocytes for at least 4 weeks. Patients with regenerated peripheral blood values but more than 5% and less than 25% myeloblasts were considered to be in partial remission (PR), as were patients fulfilling the bone marrow criteria of CR but without full recovery of peripheral blood platelet and/or white blood cell counts. Patients with persisting leukemic blasts in the bone marrow or blood or with leukemic regrowth within 4 weeks after initial response were considered as non-responders (NR). Patients dying within 6 weeks after the start of antileukemic therapy without evidence of leukemic regrowth were classified as early deaths (ED). The duration of critical cytopenia was evaluated by the time for granulocyte recovery to more than 500/l and platelet recovery to more than 20 000/l from the onset of chemotherapy. The time to CR was measured from the onset of treatment to the date of documented CR and disease-free survival from the date of documented CR to relapse or death during remission. Survival and time to treatment failure were measured by the time from the beginning of treatment to death, documentation of persisting leukemia or relapse, respectively.
Toxicity was evaluated according to the World Health Organization (WHO) grading system. 19 In all patients, clinical examinations and ECGs were performed before and 3 weeks after each cycle of chemotherapy, supplemented by ultrasound cardiography in some cases.
Statistics
The primary study end point was the rate of complete and partial remissions achieved by one or two courses of chemotherapy with aclarubicin and etoposide in a group of 35 evaluable consecutive patients with advanced AML. A remission rate of more than 35% was targeted. Secondary end points were the duration of disease-free survival in patients achieving a complete or partial remission, the hematologic and nonhematologic toxicity of the regimen, and the rate of ED and NR. An ED rate of less than 30% was targeted. Actuarial values for survival, disease-free survival, time to treatment failure, duration of neutropenia, and time to CR were calculated from Kaplan-Meier estimates.
Study conduct
Prior to therapy all patients gave their informed consent for participation in the current evaluation after having been advised about the purpose and investigational nature of the study as well as of potential risks. The study design adhered to the declaration of Helsinki and was approved by the ethics committees of the participating institutions prior to its initiation.
Results
Patient characteristics
Thirty-seven patients were entered in the study from 14 centers in Germany, all of whom were fully evaluable. The patients' ages ranged from 18 to 81 years (median 42 years; Table 1 ). All patients had received prior chemotherapy for their disease as indicated above. Twenty-seven (73%) patients had received consolidation treatment with either TAD-9 or DAV. Thirty-two (86%) patients had received high-dose cytosine arabinoside as part of induction therapy or second-line treatment. Overall, 10 (27%) patients had disease refractory to second-line therapy and 27 (73%) had second or subsequent relapses. AML subtypes were predominantly M1, M2, M4 and M5. Thirty-two patients received one course of aclarubicin and etoposide and five patients received two courses.
Antileukemic activity
Overall, 15 (40%) patients achieved a remission consisting of nine complete (24%) and six partial remissions (16%). An adequate reduction of bone marrow blasts was documented in 13 of 22 (59%) patients with evaluable bone marrow examinations on day 12, ie 1 week after completion therapy. Fourteen (38%) cases were non-responders and eight (22%) patients suffered from ED ( Table 2 ). Within the group of patients with second or subsequent relapses, nine (30%) and two (7%) patients achieved a CR and PR, respectively, while in patients with refractory relapse a PR was achieved in four cases only. The actuarial median time to treatment failure for all patients was 0.8 months. Disease-free survival for patients in remission and overall survival was 3.2 months each. Four patients in remission -two with refractory relapse and two with second relapse -underwent allogeneic or autologous bone marrow transplantation.
Side-effects
The actuarial median duration of critical neutropenia Ͻ500/l was 27 days. There was one case with prolonged neutropenia (more than 2 months). The median time to CR, ie the time to full recovery of neutrophils Ͼ1500/l and of thrombocytes Ͼ100 000/l, amounted to 46 days.
The non-hematologic side-effects that were encountered during aclarubicin and etoposide therapy are summarized in Table 3 . The most frequent side-effects were stomatitis (WHO III/IV, 48%), infections (40%), nausea/vomiting (26%) and diarrhea (24%). Pneumonia was diagnosed in 13 (31%) cases. Cardiac toxicity was mild, no episodes of ventricular arrhythmia or overt heart failure were observed. A post-treatment ultrasound cardiography, which was performed in eight patients, revealed an unchanged left ventricular ejection fraction within the normal range in all cases. Table 3 Non-hematologic side-effects 
Discussion
The current study was carried out to define the antileukemic potential of combination chemotherapy with aclarubicin and etoposide in patients with heavily pretreated AML at the stage of refractory relapse or second or subsequent relapse and hence a far advanced stage of the disease. In this group of patients the induction of another remission is difficult to achieve, especially due to the prior failure to high-dose cytosine arabinoside treatment. 5 Thus, results of third-line therapies are compromised by the resistance of the disease as well as by the relatively poor performance status of the patients, which was impaired in the majority of cases upon the onset of salvage treatment ( Table 1) . As a result, a substantial number of patients are prone to non-response to chemotherapy or to severe infectious complications, eventually leading to early death.
Given the above mentioned limitations, the results of the current trial compare favorably with other third-line regimens.
1,2,5 Overall, 40% of the patients achieved a remission, thus providing the basis for bone marrow transplantation as a further perspective. This goal was actually achieved in four patients (11%), while in another 11 cases unmaintained remissions for a median of 4 months were obtained. As anticipated, the toxicity of the aclarubicin/etoposide regimen was pronounced, with 48% of the patients suffering from severe stomatitis and 40% having severe infections. However, due to the relatively short duration of critical neutropenia (median 27 days) the rate of ED (22%) was in the range of other secondline therapies. 3, 4 Both aclarubicin [20] [21] [22] [23] [24] [25] [26] and etoposide 10, 11 have been applied as single agents to patients with newly diagnosed or previously treated AML, leading to remission rates of 13-43% and 10-25%, respectively. Combinations of aclarubicin with either standard-dose cytosine arabinoside and thioguanin, 27 low-dose cytosine arabinoside 28, 29 or BHAC, mercaptopurin and prednisone 30 yielded similar results. Especially, promising data on the antileukemic efficacy of a combination with aclarubicin and etoposide were reported, with CR rates of 34 and 36% in patients with disease refractory to first-or second-line therapy. 12, 31 However, the current patient group was pretreated more heavily, ie 28 of 37 patients had received prior sequential high-dose AraC at first relapse and first-line therapy with high-dose AraC in eight patients. Thus, the results of the present study add further evidence for a substantial efficacy of this combination in a cohort of patients with an advanced and highly unfavorable stage of the disease. Supporting the value of aclarubicin in the treatment of AML preliminary evaluations of the drug as part of first-line therapies revealed that it is at least equally effective as compared with daunorubicin. 32, 33 Following initial reports on aclarubicin-induced cardiotoxicity, which included QTc prolongation leading to ventricular fibrillation 34 as well as evidence of acute 25 and chronic 24 heart failure, subsequent studies demonstrated a good tolerability of the substance with only limited changes of ECG 26 and modest impairments of left ventricular ejection fraction. 35 Accordingly, in no case in the current trial was specific ECG changes, overt heart failure or an impairment of the left ventricular ejection fraction observed. The present data confirm a substantial antileukemic efficacy and an acceptable toxicity of aclarubicin in combination with etoposide in a cohort of patients with AML at the stage of refractory first relapse and second or subsequent relapses and warrants its further evaluation at earlier stages of therapy. Fur-thermore, the role of multidrug resistance, which has recently been shown to have a significant impact on the results of firstline therapy, 36 should be addressed in this setting in further trials.
